BluePrint is an 80-Gene Molecular Subtyping Test which allows for the classification of breast cancer into RNA-based functional molecular subtypes which is not possible using current standard pathological tests.
Breast cancer is a heterogeneous disease and the grouping of breast cancers into distinct clinically-relevant subtypes enables more informed treatment decision-making. BluePrint evaluates the functionality of receptor cell signaling and complements IHC/FISH. It provides information regarding patient chemotherapy or hormonotherapy resistance for more informed treatment decision-making.
When used in combination with MammaPrint, BluePrint allows patients to be stratified into the following subgroups:
- Luminal-type/MammaPrint Low Risk (Luminal A)
- Luminal-type/MammaPrint High Risk (Luminal B)
- HER2-type
- Basal-type
18% of clinical “luminal” patients were reclassified in a different subtype with BluePrint compared to IHC/FISH, with a significantly higher response rate to neoadjuvant chemotherapy.1 Molecular subtypes have marked differences in long-term outcome and how a patient may respond to treatment with chemotherapy including prior to surgery (neoadjuvant). MammaPrint Low-Risk, BluePrint Luminal-type A patients are unlikely to respond to neoadjuvant chemotherapy, whereas MammaPrint High Risk, BluePrint Luminal-type B, Basal-type and HER2-type patients are likely to respond to neoadjuvant chemotherapy.
References
- Whitworth, P., Beitsch, P., Mislowsky, A., et al. Ann Surg Oncol (2017) 24:669-675
